The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation
Open accessAbstract
Anti‐tumor vaccines consisting of extended CTL peptides in combination with CpG‐ODN were shown to be superior to those comprising minimal CTL epitopes and CpG‐ODN, in that they elicit stronger effector CTL responses with greater tumoricidal potential. We now demonstrate that this improved performance is primarily due to the focusing of CTL epitope presentation onto activated DC in the inflamed lymph nodes draining the vaccination site. In the case of vaccination with minimal peptides, additional APC including T and B cells are also loaded with CTL epitopes. Our data suggest that circulation of these peptide‐loaded lymphocytes leads to epitope presentation in non‐inflamed lymphoid organs distal from the vaccination site, in the absence of potent costimulatory signals required for efficient CTL priming. The resulting blend of pro‐immunogenic and tolerogenic signals, which results in suboptimal activation of the CTL response, is avoided by vaccinating with extended CTL peptides. An additional advantage of extended CTL peptide vaccines is an increased duration of in vivo epitope presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., & Aguzzi, A. (2004) · Nature Medicine · doi:10.1038/nm987 · Cited by 449
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationDendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Self-citationCancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 508
Self-citationMassarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490
Self-citationHailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 457
Lynn, G. M., Sedlik, C., Baharom, F., Zhu, Y., Ramirez-Valdez, R. A., Coble, V. L., Tobin, K., Nichols, S. R., Itzkowitz, Y., Zaidi, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0390-x · Cited by 349
Slingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299
Challenges in developing personalized neoantigen cancer vaccines
Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00937-y · Cited by 258
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Self-citationBeyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines
Stephens, A. J., Burgess-Brown, N. A., & Jiang, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696791 · Cited by 153
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
Zhu, J., Bai, L., Wang, C., Liu, J., Chen, Y., Zhang, W., Weng, J., Wei, L., & Wei, Z. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103505
Metadata
- Authors
- Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., van der Burg, S. H., & Offringa, R.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2008-04
- Volume
- 38
- Issue
- 4
- Pages
- 1033-1042
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2002623789
- Cited by
- 229
- References
- 1
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.